Teva Announces FDA Approval of ProAir® RespiClick

Industry News

Teva Pharmaceutical Industries, headquartered in Israel announced that the FDA has approved ProAir® RespiClick (albuterol sulfate) inhalation powder for the treatment and prevention of acute asthma symptoms in patients 12 years of age and older. ProAir® RespiClick is the first and only breath-actuated, dry-powder, short-acting beta-agonist (SABA) inhaler that eliminates the need for hand-breath coordination during inhalation. ProAir® RespiClick is indicated for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB). It is expected to become commercially available sometime this year.

Related Links: 

Subscribe to WXPress

Receive our newsletter and information on upcoming events.